Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Registration Number
- NCT00006123
- Locations
- πΊπΈ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
πΊπΈHackensack University Medical Center, Hackensack, New Jersey, United States
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
- Conditions
- Sarcoma
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: cyclophosphamideDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: ifosfamideDrug: irinotecan hydrochlorideDrug: vincristine sulfateProcedure: conventional surgeryRadiation: radiation therapy
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00077285
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
- Conditions
- LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 31
- Registration Number
- NCT00077116
- Locations
- π¨π
Universitaetsspital-Basel, Basel, Switzerland
π§πͺAZ Sint-Jan, Brugge, Belgium
π§πͺH. Hartziekenhuis - Roeselaere., Roeselare, Belgium
Biological Therapy in Treating Patients With Glioblastoma Multiforme
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-02-09
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT00003185
- Locations
- πΊπΈ
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-02-09
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Louisiana State University Health Sciences Center Shreveport
- Target Recruit Count
- 12
- Registration Number
- NCT00003086
- Locations
- πΊπΈ
Louisiana State University School of Medicine, Shreveport, Louisiana, United States
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Yale University
- Target Recruit Count
- 89
- Registration Number
- NCT00002679
- Locations
- πΊπΈ
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-02-03
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 15
- Registration Number
- NCT00008034
- Locations
- π¨π
Hopital Cantonal Universitaire de Geneva, Geneva, Switzerland
Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Drug: fludarabine phosphateDrug: cyclophosphamideBiological: Rituxan (rituximab)Biological: filgrastimDrug: methylprednisoloneOther: immunologic techniqueOther: laboratory biomarker analysisProcedure: autologous hematopoietic stem cell transplantationDrug: DiphenhydramineDrug: Mesna
- First Posted Date
- 2004-02-03
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT00076752
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-02-03
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00009997
- Locations
- πΊπΈ
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Lymphoma Trials Office
- Target Recruit Count
- 500
- Registration Number
- NCT00003578
- Locations
- π¨πΏ
Charles University Hospital, Prague (Praha), Czech Republic
π¬π§City Hospital - Birmingham, Birmingham, England, United Kingdom
π³π΄Norwegian Radium Hospital, Oslo, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.